{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T22:54:14Z","timestamp":1788648854453,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,26]],"date-time":"2018-12-26T00:00:00Z","timestamp":1545782400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1111\/ajt.15223","type":"journal-article","created":{"date-parts":[[2018,12,26]],"date-time":"2018-12-26T07:58:38Z","timestamp":1545811118000},"page":"907-919","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":124,"title":["Empagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety"],"prefix":"10.1016","volume":"19","author":[{"given":"Elisabeth","family":"Schwaiger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Burghart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Signorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Ristl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Kopecky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Tura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pacini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wrba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"Antlanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Schmaldienst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Werzowa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus D.","family":"S\u00e4emann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8047-2395","authenticated-orcid":false,"given":"Manfred","family":"Hecking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1111\/ajt.15223_bib1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nrneph.2011.174","article-title":"Complications associated with new-onset diabetes after kidney transplantation","volume":"8","author":"Sharif","year":"2011","journal-title":"Nat Rev Nephrol."},{"issue":"3","key":"10.1111\/ajt.15223_bib2","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/ndt\/gfs583","article-title":"Novel views on new-onset diabetes after transplantation: development, prevention and treatment","volume":"28","author":"Hecking","year":"2013","journal-title":"Nephrol Dial Transplant."},{"issue":"9","key":"10.1111\/ajt.15223_bib3","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1111\/ajt.12850","article-title":"Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions","volume":"14","author":"Sharif","year":"2014","journal-title":"Am J Transplant."},{"issue":"4","key":"10.1111\/ajt.15223_bib4","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1681\/ASN.2011080835","article-title":"Early basal insulin therapy decreases new-onset diabetes after renal transplantation","volume":"23","author":"Hecking","year":"2012","journal-title":"J Am Soc Nephrol."},{"issue":"5","key":"10.1111\/ajt.15223_bib5","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.2337\/dc12-2067","article-title":"Can new-onset diabetes after kidney transplant be prevented?","volume":"36","author":"Chakkera","year":"2013","journal-title":"Diabetes Care."},{"key":"10.1111\/ajt.15223_bib6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.trre.2015.01.001","article-title":"Antidiabetic therapy in post kidney transplantation diabetes mellitus","volume":"29","author":"Werzowa","year":"2015","journal-title":"Transplant Rev (Orlando)."},{"issue":"6","key":"10.1111\/ajt.15223_bib7","doi-asserted-by":"crossref","first-page":"478","DOI":"10.2174\/15733998113096660085","article-title":"Type 2 diabetes mellitus and Invokana: an FDA approved drug","volume":"9","author":"Akhtar","year":"2013","journal-title":"Curr Diabetes Rev."},{"issue":"12","key":"10.1111\/ajt.15223_bib8","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/ki.2009.87","article-title":"Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications","volume":"75","author":"Bakris","year":"2009","journal-title":"Kidney Int."},{"issue":"7","key":"10.1111\/ajt.15223_bib9","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrd3180","article-title":"SGLT2 inhibition\u2013a novel strategy for diabetes treatment","volume":"9","author":"Chao","year":"2010","journal-title":"Nat Rev Drug Discov."},{"issue":"10","key":"10.1111\/ajt.15223_bib10","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/dom.12307","article-title":"Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis","volume":"16","author":"Liakos","year":"2014","journal-title":"Diabetes Obes Metab."},{"issue":"22","key":"10.1111\/ajt.15223_bib11","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med."},{"issue":"7","key":"10.1111\/ajt.15223_bib12","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med."},{"issue":"4","key":"10.1111\/ajt.15223_bib13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1111\/ajt.15223_bib14","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1681\/ASN.2016030278","article-title":"Canagliflozin slows progression of renal function decline independently of glycemic effects","volume":"28","author":"Heerspink","year":"2017","journal-title":"J Am Soc Nephrol."},{"issue":"7","key":"10.1111\/ajt.15223_bib15","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s00125-016-3956-x","article-title":"SGLT2 Inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms?","volume":"59","author":"Sattar","year":"2016","journal-title":"Diabetologia."},{"issue":"3","key":"10.1111\/ajt.15223_bib16","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.kint.2015.12.038","article-title":"Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis","volume":"89","author":"Rajasekeran","year":"2016","journal-title":"Kidney Int."},{"issue":"2","key":"10.1111\/ajt.15223_bib17","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG Outcome trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care."},{"issue":"4","key":"10.1111\/ajt.15223_bib18","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S2213-8587(15)00387-3","article-title":"Post-transplantation diabetes-state of the art","volume":"4","author":"Sharif","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"10.1111\/ajt.15223_bib19","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","article-title":"Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"1","author":"Roden","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1111\/ajt.15223_bib20","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12933-015-0314-0","article-title":"Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naive patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial","volume":"14","author":"Roden","year":"2015","journal-title":"Cardiovasc Diabetol."},{"issue":"Suppl 2","key":"10.1111\/ajt.15223_bib21","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.2337\/dc11-s225","article-title":"Insulin: potential negative consequences of early routine use in patients with type 2 diabetes","volume":"34","author":"Lebovitz","year":"2011","journal-title":"Diabetes Care."},{"issue":"6","key":"10.1111\/ajt.15223_bib22","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med."},{"issue":"1","key":"10.1111\/ajt.15223_bib23","doi-asserted-by":"crossref","first-page":"9644","DOI":"10.1038\/s41598-017-09433-5","article-title":"Intravenous fluid challenge decreases intracellular volume: a bioimpedance spectroscopy-based crossover study in healthy volunteers","volume":"7","author":"Ernstbrunner","year":"2017","journal-title":"Sci Rep."},{"issue":"9","key":"10.1111\/ajt.15223_bib24","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2337\/dc15-1380","article-title":"Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care."},{"issue":"9","key":"10.1111\/ajt.15223_bib25","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.2337\/dc12-2441","article-title":"Glucose metabolism after renal transplantation","volume":"36","author":"Hecking","year":"2013","journal-title":"Diabetes Care."},{"key":"10.1111\/ajt.15223_bib26","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1210\/jc.2017-01838","article-title":"Empagliflozin treatment is associated with improved beta cell function in T2DM","volume":"103","author":"Al Jobori","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1111\/ajt.15223_bib27","unstructured":"U.S. Food and Drug Administration. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm475463.htm. Accessed April 28, 2018."},{"issue":"1","key":"10.1111\/ajt.15223_bib28","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1038\/s41598-017-02733-w","article-title":"Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep."},{"issue":"suppl 2","key":"10.1111\/ajt.15223_bib29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1365-2362.2008.02014.x","article-title":"Urinary tract infection in renal transplant recipients","volume":"38","author":"Saemann","year":"2008","journal-title":"Eur J Clin Invest."},{"issue":"2","key":"10.1111\/ajt.15223_bib30","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1053\/j.ajkd.2004.04.040","article-title":"Late urinary tract infection after renal transplantation in the United States","volume":"44","author":"Abbott","year":"2004","journal-title":"Am J Kidney Dis."}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajt.15223","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajt.15223","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajt.15223","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522090025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522090025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajt.15223","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:23:33Z","timestamp":1761629013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522090025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S1600613522090025"],"URL":"https:\/\/doi.org\/10.1111\/ajt.15223","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/ajt.15223","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}